1 January 2023 in Journal of Renal Endocrinology
Hyperuricemia is described as a serum uric acid level more than 6.0 mg/dL. It is demonstrated by basic research and clinical studies, which the elevation of uric acid level may change the renal histology and function by developing acute and chronic kidney diseases (CKDs), diabetic nephropathy and end-stage renal disease (ESRD). There is no doubt about a significant relationship between uric acid and renal impairment. However, the details of this correlation, especially; between uric acid and renal failure, are discussable. Renal vasoconstriction, antiangiogenic properties, endothelial dysfunction, proinflammatory properties, renal fibrosis, pro-oxidative properties, and alteration of renal autoregulation are the most common mechanisms, which approve the association between uric acid and renal impairment. Allopurinol administration for CKD treatment in patients with gout is one of the most discussable challenges. It should be investigated whether allopurinol can diminish the deterioration of the glomerular filtration rate (GFR) in CKD patients who are at risk of ESRD. Some previous studies reported that allopurinol decreases the CKD incident risk, but others could not confirm this association. The benefit or risks of allopurinol in different stages of CKD, dialysis, and renal transplant are discussed in this study.
1 January 2023 in Journal of Renal Endocrinology
This review critically discusses the importance of screening patients with type 1 diabetes and hypothyroidism for related autoimmune diseases. It provides insights into the prevalence of thyroid disorders and diabetes mellitus, as well as the connection between T1D and hypothyroidism. The review also highlights the benefits of early detection and the implications for health policy, practice, research, and medical education. Overall, this article provides valuable information for healthcare providers on how to screen patients for related autoimmune diseases and provide them with the best possible care.
29 November 2023 in Journal of Nephropharmacology
Emerging cancer in individuals with cardiovascular disease: Exploring the intersection of reverse cardio-oncology and nephropharmacology